What is the studied mechanism behind GHK-Cu?

GHK-Cu is studied as a high-affinity copper-binding tripeptide. Published research examines how the GHK sequence chelates Cu²⁺ and how that copper delivery is associated with downstream cellular signalling relevant to connective-tissue biology in laboratory models.

Does GHK-Cu mechanism research involve human trials?

The majority of published GHK-Cu mechanism research is conducted in cell-culture and animal-model systems. This page describes laboratory-level biochemical and cellular mechanisms studied in published literature — it is not a clinical claim and is not medical advice.

Is GHK-Cu from REVIVE LAB UAE intended for use in humans?

No. GHK-Cu supplied by REVIVE LAB UAE is a research-use-only laboratory reference material. It is not intended for human or veterinary use or consumption under any circumstance.

What extracellular matrix components does GHK-Cu research focus on?

Published research most commonly focuses on collagen, decorin, and matrix metalloproteinase (MMP) activity as the extracellular matrix components most studied in association with GHK-Cu's copper-delivery mechanism.

BPC-157: reading the research without the claims

Published 27 August 2026 · REVIVE Peptides Research Desk · 7 min read

TL;DR. Research Use Only — Not Intended for Human Use. What BPC-157 is, what the Sikiric group and others have published, why the evidence is almost entirely preclinical, and its anti-doping status. REVIVE LAB UAE stocks BPC-157 5 mg at AED 490, ≥ 99.2% (HPLC) purity, strictly as a laboratory reference material. This article contains no dosing, administration or usage guidance.

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — derived from a sequence described in human gastric juice. The name stands for Body Protection Compound. It is sometimes called a stable gastric pentadecapeptide in the literature, a reference to its reported resistance to degradation in gastric acid.

It is a synthetic construct, not a hormone or a licensed drug, and it has no marketing authorisation in any major jurisdiction.

What the literature reports

The great majority of the published work comes from Predrag Sikiric's group in Zagreb, across several decades and a wide range of injury models — gastrointestinal lesions, tendon and ligament, muscle, nerve, and vascular models. Their 2011 review in Current Pharmaceutical Design is the usual starting point for reading it.

The mechanistic strand most often cited outside that group concerns angiogenesis and growth-factor signalling. Chang and colleagues reported effects on tendon fibroblast outgrowth and migration in culture, and in later work examined growth hormone receptor expression in those cells.

Why the evidence is weaker than it looks

The volume of papers is genuinely large, but it is concentrated in animal models and in one research group, and independent replication in humans is thin. A long citation list is not the same as a robust, independently reproduced clinical effect.

There are no large randomised controlled trials establishing a human indication. That is the honest state of the evidence, and it is the reason this article describes mechanisms and models rather than outcomes.

Regulatory and anti-doping status

BPC-157 was added to the World Anti-Doping Agency Prohibited List, in the peptide hormones and growth factors class, effective from 2022. Any athlete subject to anti-doping rules should treat it as prohibited in and out of competition.

It is supplied here strictly as a laboratory reference material. It is not a medicine, and this article recommends no dose, route or schedule.

Catalogue item

Item	BPC-157
Strength	5 mg
Purity	≥ 99.2% (HPLC)
Price	AED 490
Delivery	Same-day Dubai dispatch before 4 PM, 24-hour delivery across all seven emirates.

Research Use Only — Not Intended for Human Use. This article is provided for research and educational purposes and describes published findings only. It recommends no dose, route, schedule or use. REVIVE LAB UAE supplies reference materials for laboratory research; these are not medicines and are not for human or veterinary consumption. Anyone considering the use of any compound in humans should do so only under qualified medical supervision.

References

Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780.
Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077.
Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865.
World Anti-Doping Agency. Prohibited List — S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics.